Baidu
map

系统性红斑狼疮患者何时可以考虑妊娠?

2016-03-25 佚名 中华医学杂志

系统性红斑狼疮(SLE)患者必须同时满足下述条件才可以考虑妊娠 1)病情不活动且保持稳定至少6个月; 2)糖皮质激素的使用剂量为泼尼松 15mg/d(或相当剂量)以下; 3)24h尿蛋白排泄定量为0.5克以下; 4)无重要脏器损害; 5)停用免疫抑制药物如环磷酰胺、甲氨蝶呤、雷公藤、霉酚酸酯等至少6个月

中国系统性红斑狼疮研究协作组专家组

系统性红斑狼疮(SLE)患者必须同时满足下述条件才可以考虑妊娠

1)病情不活动且保持稳定至少6个月;

2)糖皮质激素的使用剂量为泼尼松 15mg/d(或相当剂量)以下;

3)24h尿蛋白排泄定量为0.5克以下;

4)无重要脏器损害;

5)停用免疫抑制药物如环磷酰胺、甲氨蝶呤、雷公藤、霉酚酸酯等至少6个月;对于服用来氟米特的患者,建议先进行药物清除治疗后,再停药至少6个月后才可以考虑妊娠。

以下情况属于妊娠禁忌证

1)严重的肺动脉高压(估测肺动脉收缩压>50mmHg,或出现肺动脉高压的临床症状);

2)重度限制性肺部病变(用力肺活量(FVC)<1 升);

3)心功能衰竭;

4)慢性肾功能衰竭(血肌酐SCr >2.8mg/dl);

5)既往有严重的子痫前期或即使经过阿司匹林和肝素治疗仍不能控制的HELLP综合征;

6)过去6个月内出现脑卒中;

7)过去6个月内有严重的狼疮病情活动。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=292269, encodeId=ebbd2922694f, content=说的很详细.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/25/f9c103b74b05f7c5951ad79adf5be80f.jpg, createdBy=49642274853, createdName=spake, createdTime=Fri Mar 02 11:01:29 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016930, encodeId=2c852016930ca, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 30 22:36:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387167, encodeId=d89a138e16766, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Sun Mar 27 00:36:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436072, encodeId=074214360e2d2, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Mar 27 00:36:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73769, encodeId=3dcbe376978, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:22:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
    2018-03-02 spake

    说的很详细.谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=292269, encodeId=ebbd2922694f, content=说的很详细.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/25/f9c103b74b05f7c5951ad79adf5be80f.jpg, createdBy=49642274853, createdName=spake, createdTime=Fri Mar 02 11:01:29 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016930, encodeId=2c852016930ca, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 30 22:36:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387167, encodeId=d89a138e16766, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Sun Mar 27 00:36:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436072, encodeId=074214360e2d2, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Mar 27 00:36:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73769, encodeId=3dcbe376978, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:22:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=292269, encodeId=ebbd2922694f, content=说的很详细.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/25/f9c103b74b05f7c5951ad79adf5be80f.jpg, createdBy=49642274853, createdName=spake, createdTime=Fri Mar 02 11:01:29 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016930, encodeId=2c852016930ca, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 30 22:36:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387167, encodeId=d89a138e16766, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Sun Mar 27 00:36:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436072, encodeId=074214360e2d2, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Mar 27 00:36:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73769, encodeId=3dcbe376978, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:22:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=292269, encodeId=ebbd2922694f, content=说的很详细.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/25/f9c103b74b05f7c5951ad79adf5be80f.jpg, createdBy=49642274853, createdName=spake, createdTime=Fri Mar 02 11:01:29 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016930, encodeId=2c852016930ca, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 30 22:36:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387167, encodeId=d89a138e16766, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Sun Mar 27 00:36:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436072, encodeId=074214360e2d2, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Mar 27 00:36:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73769, encodeId=3dcbe376978, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:22:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
    2016-03-27 zhouqu_8
  5. [GetPortalCommentsPageByObjectIdResponse(id=292269, encodeId=ebbd2922694f, content=说的很详细.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/25/f9c103b74b05f7c5951ad79adf5be80f.jpg, createdBy=49642274853, createdName=spake, createdTime=Fri Mar 02 11:01:29 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016930, encodeId=2c852016930ca, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 30 22:36:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387167, encodeId=d89a138e16766, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Sun Mar 27 00:36:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436072, encodeId=074214360e2d2, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Mar 27 00:36:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73769, encodeId=3dcbe376978, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Fri Mar 25 19:22:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
    2016-03-25 1de304d2m86(暂无匿称)

    值得学习

    0

相关资讯

Lupus:利妥昔单抗治疗SLE的meta分析

系统性红斑狼疮(SLE)是一种反复发作的具有多种临床表现及血清学异常的疾病,全身多系统器官均可受累。SLE以妇女及儿童多发,非洲裔、西班牙裔及亚裔人群高发。患者诊断10年内的死亡率高达10%。本病的治疗目标主要是诱导并维持缓解、避免可能的药物毒副作用。糖皮质激素、抗疟药以及环磷酰胺、霉酚酸酯、硫唑嘌呤等免疫抑制剂是本病的主要治疗药物。然而上述药物的疗效有限,治疗后有病情复发的风险,且长期用药的毒副

Lupus:SLE与游离脂肪酸FFA

游离脂肪酸(FFA)是胰岛素抵抗和动脉粥样硬化的发病机制的有关影响因素。炎性细胞因子能促进脂肪分解和游离脂肪酸增加,使血管内皮的功能发生障碍同时相应的增加了患动脉粥样硬化的风险。 我们假设炎症发生与游离脂肪酸的浓度的增加有关,那到底FFA的升高会不会导致系统性红斑狼疮(SLE)的患者发生动脉粥样硬化和胰岛素抵抗呢?来自美国范德堡大学医学院风湿病研究所的Ormseth博士等给我们答案。 实验选取

Lupus:高龄发病的SLE患者生存率更低

系统性红斑狼疮(SLE)是一种病因不明的异质性自身免疫性疾病。患者可表现为相对良性的病程或急进而严重的病程,甚至导致器官衰竭乃至死亡。SLE主要在20或30多岁的女性人群中发病,但其性质和严重程度会因年龄而异。疾病的严重程度和临床表现在“早发组”和“迟发组”会有不同。 一些队列研究专门研究'“迟发性SLE”。其定义为50岁后确诊为SLE的患者。据报道“迟发组”与年轻的

Ann Rheum Dis:atacicept 对预防SLE红斑有效

目的:在系统性红斑狼疮(SLE)的治疗进展,许多患者仍然在疾病中挣扎,需要承受各种药物的副作用。目前出现的Atacicept是一种融合蛋白,它可以阻止B淋巴细胞刺激因子和增殖诱导配体,所以研究者假设对SLE患者的治疗有效果。方法:采取双盲安慰剂-对照试验,将中重度SLE病人随机分为用药组与安慰剂对照组。用药组随机予皮下注射75mg或150mg的atacicept,对照组给予安慰剂;以每周两次,共4

Ann Rheum Dis:SLE长期缓解率对预后结局的提示

目的:评估白人SLE患者长期缓解的发生率和与累及损伤之间的关系。方法:研究纳入1990年至2009年之间被诊断为SLE的白人患者,一部分包括2009年至2013年的病例。研究者将连续5年维持缓解的情况定义长期缓解。使用系统性红斑狼疮活动指数(SLEDAI-2K)定义缓解的三个水平:完全缓解:脱离皮质激脂激素和免疫抑制剂使用的患者;不使用糖皮质激素的临床缓解:不使用糖皮质激素的血清学意义上的活动性临

Rheumatology:系统性红斑狼疮患者普遍存在关节侵蚀症状

关节表现常常是系统性红斑狼疮(SLE)患者最常见和最早出现的临床症状。临床判断SLE的关节病变常应用ACR非侵蚀性关节炎的诊断标准,但SLE也有非侵蚀性变形性关节炎(Jaccoud关节)和伴关节侵蚀畸形的关节炎(Rhupus综合征)。而目前对SLE关节炎的研究却较少。 为了探讨核磁共振(MRI)在SLE关节炎的诊断价值和SLE关节炎的临床特点,爱尔兰的Ball教授等做了一项病例对照研究,

Baidu
map
Baidu
map
Baidu
map